2 results match your criteria: "Yale School of Medicine (K.F.F.[Affiliation]"
Predicting Major Adverse Events in Patients Undergoing Transcatheter Left Atrial Appendage Occlusion.
Circ Arrhythm Electrophysiol
April 2024
Section of Cardiovascular Medicine, Department of Medicine, Yale School of Medicine (K.F.F., E.L.O., J.P.C., J.V.F.).
Article Synopsis
- The National Cardiovascular Data Registry's LAAO Registry includes most LAAO procedures in the U.S., and this study aimed to create a model predicting in-hospital adverse events for patients undergoing LAAO with Watchman FLX.
- The study analyzed data from 41,001 procedures, using logistic regression on both development and validation cohorts to identify key predictors of major adverse events, such as age, sex, and health status.
- The resulting risk model showed moderate accuracy and offered a simplified bedside risk score, enabling healthcare professionals to better predict risks and improve decision-making in patient care.
Use of Administrative Claims to Assess Outcomes and Treatment Effect in Randomized Clinical Trials for Transcatheter Aortic Valve Replacement: Findings From the EXTEND Study.
Circulation
July 2020
Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Boston, MA (J.B.S., Y.Z., H.T., L.R.V., C.S., D.S.K., R.W.Y.).
Background: Whether passively collected data can substitute for adjudicated outcomes to reproduce the magnitude and direction of treatment effect observed in cardiovascular clinical trials is not well known.
Methods: We linked adults ≥65 years of age in the HiR (US CoreValve Pivotal High Risk) and SURTAVI trials (Surgical or Transcatheter Aortic Valve Replacement in Intermediate-Risk Patients) to 100% Medicare inpatient claims, January 1, 2011, to December 31, 2016. Primary (eg, death and stroke) and secondary trial end points were compared across treatment arms (eg, transcatheter aortic valve replacement [TAVR] versus surgical aortic valve replacement [SAVR]) using trial-adjudicated outcomes versus outcomes derived from claims at 1 year (HiR) or 2 years (SURTAVI).